MedTrace Logo

Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

NCT05039723 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-07-07

No results posted yet for this study

Summary

The purpose of this study is to determine the improvement in signs of photoaging and subject satisfaction after combination, global facial and/or neck treatment with IncobotulinumA (Xeomin), HA (Belotero) and/or calcium hydroxyapatite (Radiesse+, Radiesse Classic). All products will be used on-label FDA-cleared indications.

Conditions

  • Photoaging

Interventions

DRUG

Radiesse, Xeomin, Belotero

Rejuvenation with Radiesse, Xeomin, Belotero

Sponsors & Collaborators

  • Merz North America, Inc.

    collaborator INDUSTRY

  • Main Line Center for Laser Surgery

    lead OTHER

Principal Investigators

  • Kachiu Lee, MD · Main Line Center for Laser Surgery

  • Eric Bernstein, MD · Main Line Center for Laser Surgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-03-01
Completion
2022-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05039723 on ClinicalTrials.gov